Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ying Huang

Ying is China Commercial Editor with PharmAsia News. She has been working with international healthcare business intelligence since 2007, covering China and South East Asian countries including Singapore, Taiwan, Thailand, Vietnam, the Philippines, Malaysia and Indonesia. Her work covers health care reform, new drug development, M&A and financing, partnering, business strategies and outsourcing. 

Prior to joining Informa, Ying was the China Bureau Editor of BioPharm Insight, a Financial Times Group product. She led the investigative coverage on the important situations taking place within the healthcare industry, delivering breaking news and insights on the biopharmaceutical industry in China and Southeast Asia. 

Ying has covered academic and industry meetings in China and Asia where she has interviewed C-level executives and key opinion leaders. She has also worked as an international business development assistant at a China-listed pharmaceutical company.

Ying holds a Master's degree in Public Health from the University of Westminster in London, and a bachelor’s degree in biotechnology.

Advertisement
Set Alert for Articles By Ying Huang

Latest From Ying Huang

Key Role For China As Sanofi’s Emerging Markets Business Grows

Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.

BioPharmaceutical China

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Deals Business Strategies

Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals

Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.

Deals Business Strategies

WuXi Biologics To Be ‘World’s No.1’ Biologics Maker

WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.

Biologics Business Strategies

India Presses Chinese API Firms Over Quality Concerns

Tougher regulatory scrutiny by India amid its massive reliance on such raw materials from China is anticipated, but the current Indian inspection action is just 'normal regulatory duties,' a Shanghai-based regulatory officer said.

Policy Drug Safety

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Deals Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register